Eli Lilly and Regeneron are leading the push to treat congenital deafness with gene therapies, seeking a piece of a potential ...
What is the difference between in-home therapy and center-based therapy for children receiving ABA therapy? The answer is explored in a HelloNation article featuring insights from Rob Shapiro of ...
The HelloNation article further highlights the value of collaboration between therapists and families. Parents often observe behaviors in settings that therapists may not see directly. Sharing these ...
Using claims data instead of self-reports, a team of researchers in Germany evaluated adherence to endocrine therapy on recurrence and mortality in early breast cancer. High adherence to endocrine ...
A new, highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance in an area where CAR-T cells have long struggled. But significant ...
CLL17 suggests similar 3-year efficacy for ibrutinib monotherapy, venetoclax–obinutuzumab, and ibrutinib–venetoclax, reinforcing that regimen selection often hinges more on logistics than short-term ...
How would you feel if your therapist’s notes – your darkest thoughts and deepest feelings – were exposed to the world? For 33,000 Finnish people, that became a terrifying reality, with deadly ...
The X post also highlighted AI's potential in various sectors ranging from improving healthcare to strengthening national security. Brockman even noted personal experiences with his wife's healthcare ...
Hosted on MSN
A promising new cancer therapy shows market progress
Donald Trump impeachment odds as approval rating hits uncharted territory Tennessee set to execute woman for first time in over 200 years Santa Clara coach rips refs after Kentucky stunner in NCAA ...
SAN DIEGO (KGTV) - The family of a 4-year-old girl given a grim diagnosis is giving thanks this holiday season amid some stunning signs in the past few weeks. A groundbreaking treatment taken on by ...
Nov 24 (Reuters) - (This Nov 24 story has been corrected to fix the pricing for Zolgensma to $2.5 million from $2.1 million in paragraph 4) The U.S. Food and Drug Administration has approved Novartis' ...
Evidence of objective responses across multiple CAR-T cell and other T cell therapies has established the clinical potential of immune cell therapies beyond haematological malignancies. The field ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results